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Abstract
Background: Platelets are rich in mediators able to positively affect cell activity in wound healing. Aim of this study
was to characterize the effect of different concentrations of human pooled allogeneic platelet lysate on human cells
involved in the different phases of wound healing (inflammatory phase, angiogenesis, extracellular matrix secretion
and epithelialization).
Methodology/Principal Findings: Platelet lysate effect was studied on endothelial cells, monocytes, fibroblasts and
keratinocytes, in terms of viability and proliferation, migration, angiogenesis, tissue repair pathway activation
(ERK1/2) and inflammatory response evaluation (NFκB). Results were compared both with basal medium and with a
positive control containing serum and growth factors. Platelet lysate induced viability and proliferation at the highest
concentrations tested (10% and 20% v/v). Whereas both platelet lysate concentrations increased cell migration, only
20% platelet lysate was able to significantly promote angiogenic activity (p<0.05 vs. control), comparably to the
positive control. Both platelet lysate concentrations activated important inflammatory pathways such as ERK1/2 and
NFκB with the same early kinetics, whereas the effect was different for later time-points.
Conclusion/Significance: These data suggest the possibility of using allogeneic platelet lysate as both an
alternative to growth factors commonly used for cell culture and as a tool for clinical regenerative application for
wound healing.
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Introduction
Wound healing is a dynamic process highly dependent on
the coordinated functions of inflammatory cells, endothelial
cells, fibroblasts, and keratinocytes, with the ultimate goal of
restoring skin integrity [1]. This process is a complex
integration of cascades, which requires multiple cytokines and
growth factors for different stimulatory and inhibitory functions
to initiate and direct different phases. Factors involved in
wound healing include platelet-derived growth factor (PDGF),
transforming growth factor (TGF) and vascular endothelial
growth factors (VEGF). Recombinant growth factors advent
was followed by their premature and empiric introduction into
clinical practice for wound healing treatment, in order to
reproduce the physiological process. However, few of them are
available for clinical use and they have practical limitations due
to their short half-life and excessive cost. The limited success
and heterogeneous clinical results obtained by the use of
single growth factors are probably related to the requirements
for multiple signals to achieve a complete regeneration
process, assuming that no single exogenous agent can
effectively mediate all aspects needed for tissue repair [2].
Thus, delivery of a wide range of biological mediators is
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probably required for efficient and complete healing, recreating
and propagating the normal sequence of events.
Platelets play a critical role in wound healing, actively
promoting cell recruitment, tissue regeneration and matrix
remodelling [3], angiogenesis and blood vessel maturation [4].
These effects are largely due to the high content of bioactive
molecules such as growth factors and mediators, released by
activated platelets during blood coagulation [5]. The increased
understanding of the physiological roles of platelets in wound
healing after tissue injury led to the idea of using platelets, the
natural source of growth factors, as therapeutic tools. Local
application of concentrated platelet preparations might achieve
a complex of growth factors which stimulates the healing
process in a more physiological way.
The clinical use of platelets for wound healing applications is
nowadays restricted to autologous platelet gels. The efficacy of
topical platelet gel application has been evaluated in both
animal and clinical studies, observing a significant
improvement in wound healing [6]. However, the process of
obtaining autologous platelet gel is difficult to standardize and
impractical for extensive use. In fact, platelet profiles and
effects change in relation to the properties of original blood
samples and methods of fabrication [7]. Although non-
homogeneous results have been reported, several studies
regarding the use of platelet concentrates or gels showed
reduced inflammation, improved bone regeneration and
improved hard and soft tissue wound healing [6]. In addition to
the treatment of chronic wounds and ulcers, platelet derivatives
and platelet-released growth factors find application also in
orthodontics, dental surgery and plastic surgery [2].
Another platelet derivative with potential clinical application is
platelet lysate (PL). PL, obtained by repeated freezing-thawing
of platelet enriched blood samples, contains a cocktail of
immediately available growth factors and cytokines that can
promote tissue regeneration. Human PL has been recently
proposed as an alternative to fetal bovine serum (FBS) for
clinical-grade cell expansion for regenerative medicine [8,9], as
FBS carries the risk of xenogenic immune reactions and of
transmitting viral and prion diseases. PL was shown to be
superior to or at least the same compared to FBS in most
studies regarding stem cells [8] and bone marrow
mesenchymal cells expanded in medium supplemented with
PL instead of FBS have been used in clinical trials [10].
However, PL donor age affects proliferation, senescence and
osteogenic differentiation of MSCs [11].
The aim of this study was to further characterize the wound
healing properties of increasing concentrations of human
allogeneic pooled PL on cells involved in the different phases
of wound healing. In particular, the effect of increasing
concentrations of PL was studied on human cell types such as
monocytes, endothelial cells, fibroblasts and keratinocytes.
Further analyses on the activation of intracellular pathways
involved in both angiogenesis and tissue repair were performed
with selected PL concentrations. PL at the two highest
concentrations tested was able to increase in a similar way cell
viability, proliferation and migration of different cell populations.
On the other way, a differential effect of these two
concentrations was observed regarding angiogenesis and
intracellular pathway activation.
Materials and Methods
Ethics statement
Transfusion units of platelet rich concentrates, derived from
buffy coats, were obtained from voluntary healthy blood donors
at Blood Transfusion Center "SS. Giacomo e Cristoforo
Hospital", Massa, Italy (www.usl1.toscana.it), a structure that
has been accredited by Regional Health Authority to collect
whole blood and prepare donor-derived platelet concentrates.
The approval from institutional review board or ethics
committee was thus not necessary. Written informed consent
from the blood donors was obtained for using platelet rich
concentrates for research.
Platelet lysate preparation
Whole blood was separated into platelet-rich plasma (PRP)
and erythrocytes by centrifugation (300 g for 10 min). PRP was
then centrifuged at 1500 g for 15 min to obtain the platelet
pellet. After washing, the pellet was gently resuspended in
NaCl (0.9% w/v) saline solution and concentrated to 1.3x109
platelets/ml. Finally, to obtain PL, the platelet concentrate was
frozen (-80°C) and thawed (37°C) three times and stored in
aliquots at -80°C until use. PL samples were vortexed for 1 min
to obtain a homogeneous suspension before use. Pooled
samples prepared from PRP obtained from five different donors
were used to minimize variations between donors.
Pro-angiogenic growth factor quantification in platelet
lysate
The levels of PDGF-AB, TGF-β1 and VEGF were assessed
in PL samples using enzyme-linked immunosorbent assays for
these factors (Quantikine, R&D Systems, Inc., Minneapolis,
MN, USA), according to manufacturer’s instructions. Samples
for TGF-β1 analysis were acid activated with 1 N HCl. Growth
factor concentrations were measured in triplicate in three
different samples.
Cell isolation and culture
PL biological effect on cell viability, proliferation, migration,
angiogenesis, intracellular pathways activation and
inflammatory response was performed using four different
human cell types involved in the different phases of wound
healing: monocytes, endothelial cells, fibroblasts and
keratinocytes.
THP-1 (human acute monocytic leukemia cell line, ICLC
HTL97014) were maintained at 2–9x105 cells/ml cell density in
RPMI 1640 supplemented with 10% FBS, 2 mM L-Glutamine,
100 μg/ml streptomycin and 100 U/ml penicillin. Each
experiment was performed on cells that demonstrated viability
rates >95% after staining with Trypan blue dye for dead cell
exclusion.
Human umbilical vein endothelial cells (HUVECs) were
obtained by treatment with 0.1% collagenase type II
(Worthington Biochemical Corporation, Lakewood, NJ, USA)
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and 0.5% albumin solution to allow endothelial cell detachment
from the vessel wall [11]. Isolated cells were cultured in
Medium 199, supplemented with 20% FBS, 2mM L-Glutamine,
100 μg/ml streptomycin, 100 U/ml penicillin, 100 μg/ml heparin
from porcine intestinal mucosa and 50 μg/ml epithelial growth
factor (EGF). Experiments were performed at passage 3, using
a pool from three different donors.
Human dermal fibroblasts HFFF2 (ICLC HL97002) and
dermal keratinocytes NCTC 2544 (ICLC HL95002) were
cultured in DMEM supplemented with 10% FBS, 2 mM L-
Glutamine, 100 μg/ml streptomycin and 100 U/ml penicillin.
Medium was routinely changed every 3 days and at
confluence cells were subcultured (split ratio 1:3) by
trypsinization (0.5% trypsin/0.02% EDTA).
The culture media described for each cell type were defined
as complete media. Experiments on PL effects were performed
in absence of serum and EGF.
All the cell cultures were incubated at 37°C in a humidified
atmosphere with 5% CO2.
Culture media, reagents and serum were purchased from
Sigma-Aldrich (Saint Louis, MO, USA).
Cell viability assay
Cell viability was assessed using the XTT colorimetric assay
(Sigma-Aldrich) based on the reduction of sodium 2,3-bis(2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide
inner salt (XTT), to an orange soluble formazan by the
succinate dehydrogenase system of the mitochondrial
respiratory chain. The reaction requires the presence of an
electron coupling reagent, N-methyldibenzopyrazine methyl
sulfate (PMS), serving as an intermediate electron acceptor.
Only viable cells with active mitochondria reduce significant
amounts of XTT to formazan.
HUVECs were seeded into pregelatinized 96-well plates at a
density of 8×103 cells per well. After 24 hours of incubation,
when cell growth was in logarithmic phase, the medium was
carefully decanted and replaced with 200 μl/well of serum-free
medium containing 1, 5, 10 or 20% (v/v) PL. Complete medium
was used as a reference. After a 48-hours exposure, the viable
cell number was determined by XTT dye reduction. A XTT (1
mg/ml) and PMS (0.025 mM) labelling mixture was added to
each well and incubated for 4 hours at 37°C. At the end of
incubation time, the optical density (OD) was measured at 450
nm wavelength using a microplate reader (Spectrafluor Plus;
TECAN Austria GmbH, Grödig, Austria). The percentage of cell
viability was calculated vs. the complete medium (assumed as
100%).
Cell proliferation assay
Cell proliferation was evaluated by 5-bromo-2'-deoxyuridine
(BrdU) assay. BrdU is incorporated instead of thymidine into
the DNA of new synthesis, so BrdU incorporation is a suitable
method for the quantitative measurement of cell proliferation.
HUVECs were seeded onto pregelatinized 96-well plates at a
density of 5x103 cells/well for 24 hours. After that, when cell
growth was in the logarithmic phase, the medium was carefully
decanted and replaced with 200 μl/well of medium containing
PL (1, 5, 10 or 20%). Complete medium was used as a
reference. After 48 hours of PL incubation, cell proliferation
was assessed by BrdU assay (Roche Diagnostics, Mannheim,
Germany). BrdU reagent was added to each well and after 4
hours of incubation the assay was performed following the
procedure prescription. The OD was measured at 450 nm
wavelength using the microplate reader. The percentage of cell
proliferation was calculated vs. the complete medium
(assumed as 100%).
Monocyte chemotaxis assay
Monocyte chemotaxis was measured using a 6.5mm
Transwell® with 5.0 µm pore polycarbonate membrane insert
(Corning Costar, Cambridge, MA, USA). THP-1 cells were
resuspended at 5x105 cells/ml and 200 µl of cell suspension
were transferred to the upper chamber of each transwell. The
lower chamber was filled with 400 µl of medium containing PL
at different concentrations (5, 10 or 20%). For control wells,
serum-free medium and Monocyte Chemotactic Protein-1
(MCP-1, 10 ng/ml) enriched medium were used as chemotactic
negative and positive control, respectively. Recombinant
human MCP-1 was obtained from Invitrogen Corp. (Carlsbad,
CA, USA).
THP-1 cells were allowed to transmigrate for 120 minutes in
humidified atmosphere with 5% CO2. Cells migrated through
the polycarbonate filter pores in response to chemoattractant
stimuli were then counted by Bürker chamber under light
microscopy.
Scratch closure assay
PL effect on wound healing-associated migration was
assessed employing scratch-wounded keratinocyte and
fibroblast monolayer models [5,12]. Briefly, 8x104 keratinocytes
NCTC 2544 and 5x104 fibroblasts HFFF2 were seeded into 24-
well plates, cultured to confluence and scratched by scraping
with a 0.1–10 µL pipette tip. Following PBS washes, cultures
were re-fed with 500 μl/well of PL diluted at different
concentration (5, 10 and 20%) in serum-free culture medium.
Control wells received serum-free medium or complete culture
medium.
At 0, 6, 18, 24, 48 and 72 hours after scratching, digital
images of cells were captured by a phase contrast microscope
(Axiovert 25, Zeiss, Milan, Italy; O.M. 50X) equipped with a
digital camera (EOS 1000D, Canon, Milano, Italy). Scratch
closure was qualitatively analyzed at each time-point with
respect to time 0. For a quantitative evaluation, scratch closure
was determined as the difference between scratch width at
time 0 and each time-point. Each well was marked below the
plate surface by drawing a vertical line, to allow identification of
the same scratched area in order to take consistent pictures.
Scratch area was measured using Image J software (NCBI).
Migration rate was expressed as percentage of scratch closure
compared to the initial area and was calculated as follows =
[(At0 -At)/At0]*100, where At0 is the scratch area at time 0, and
At is the correspondent scratch area at 6, 18, 24, 48 or 72
hours. The values shown are the means of three wells from
three independent experiments.
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In vitro angiogenesis assay
To assess the potential effect of PL on in vitro angiogenesis,
HUVECs were treated with PL for 48 hours before being
detached and seeded on Matrigel.
Briefly, HUVECs (7x104 cell/well) were seeded in complete
medium on gelatin-coated 6-well plates. At subconfluence,
medium was replaced with serum-free medium in absence (0%
PL) or in presence of PL (10% and 20%). Complete medium
was used as a reference. After 48 hours of incubation at 37°C,
5% CO2, cells were detached and their number and viability
was assessed by Trypan Blue staining. 7x104 cells/well were
then seeded on 24-well plates pre-coated with 300 μl of 10
mg/ml Matrigel (BD Biosciences, San Jose, CA, US), thawed
on ice at 4°C, and allowed to solidify at 37°C for 30 min before
cell seeding [13]. After 4 and 8 hours of incubation at 37°C,
tubules were observed under an inverted microscope (Hund,
Wetzlar, Germany) equipped with a digital camera (Nikon,
Sesto Fiorentino, Italy). Pictures (n=10, 10X magnification)
captured after 8 hours were analyzed by the image analysis
software ImageJ (public domain, Image Processing and
Analysis in Java, National Institutes of Health), with the plug-in
AngioJ for angiogenesis assay. Morphometric parameters
(area %, tubule total length and number of branching points)
were calculated versus the complete medium (assumed as
100%).
Activation of intracellular pathways and inflammatory
response
Extracellular-signal-regulated protein kinase (ERK1/2) and
nuclear factor κB (NFκB) activation was detected by specific
commercial immunoenzymatic assay (Fast Activated Cell-
based ELISA, FACE, Active Motif, Carlsbad, CA, USA),
enabling monitoring of the levels of proteins activated by
phosphorylation. Briefly, HUVECs were seeded on 96-well
plates and treated with 0, 10 or 20% PL in serum-free medium
for 15, 30 and 60 minutes (ERK1/2) or 1, 24 and 48 hours
(NFκB). Complete medium, containing both EGF and 20%
FBS, was used as a positive control. Next, cells were fixed and
anti-phospho-protein or anti-total protein (primary antibodies)
were added into the wells and incubated. After washing, an
anti-mouse IgG conjugated to horseradish peroxidase (HRP)
(secondary antibody) was added to the wells for 1 hour. A TMB
(3,3',5,5' tetramethyl-benzidine) substrate solution was added
to the wells and color developed in proportion to the amount of
protein. Absorbance values (OD450) were normalized for the cell
number in each well, using the Crystal Violet 0.1% solution
assay (OD595). The values of total and phosphorylated proteins
were calculated by the value normalization to the ratio
OD450/OD595 of control cells and plotted.
Statistical analysis
Each test was conducted at least three separate times.
Results are expressed as mean ± S.D. of six replicate wells for
each samples and controls.
Data were analyzed by StatViewTM 5.0 software (SAS
Institute, Cary, NC, USA). The means were statistically
compared by the independent Student’s t-test. Values of
p<0.05 were considered statistically significant.
Results
Pro-angiogenic growth factor quantification in platelet
lysate
Mean content (± SD) of PDGF-AB, TGF-β1 and VEGF
measured by ELISA assay in PL samples were respectively 42
± 9 ng/ml, 64± 5 ng/ml and 740 ± 110 pg/ml. These
concentrations are approximately equivalent to a growth factor
content of 8.4 ng/ml (PDGF-AB), 12.8 ng/ml (TGF-β1) and 148
pg/ml (VEGF), for cell treatment with 20% v/v PL.
Cell viability assay
Cell viability of HUVECs exposed to increasing PL
concentrations for 48 hours was evaluated by XTT assay.
HUVEC viability as compared to the complete control medium
(assumed as 100%) is shown in Figure 1A. HUVECs incubated
in serum-free medium showed a PL dose-related increase in
mitochondrial metabolism. In particular, the removal of serum
and EGF from culture medium reduced the cell viability to 28%
(0% PL), with no significant variation by adding 1 or 5% PL. A
significant increase in cell viability (p<0.01 vs. 0% PL) was
observed with higher concentrations of PL (10 and 20%),
comparable to the complete medium.
Cell proliferation assay
Cell proliferation of HUVECs exposed to increasing PL
concentrations for 48 hours under serum-free conditions was
determined by BrdU assay. DNA synthesis as compared to the
complete culture medium (assumed as 100%) is shown in
Figure 1B. The 1 and 5% PL were not significantly different
from the negative control (0% PL), whereas 10 and 20% PL
induced a significant increase in cell proliferation(p<0.01 vs.
0% PL), comparable to complete medium.
Monocyte chemotaxis assay
PL effect on cell migration rate was assessed by a
chemotaxis assay, using the chemoattractive protein MCP-1 as
a positive control (Figure 2). Both 10 and 20% PL produced a
comparable significant increase (p<0.05) in migrating cell
number as compared to both serum-free condition and 5% PL.
Scratch closure assay
PL effect on cell migration was determined by scratch assay
with dermal keratinocytes (NCTC 2544) and fibroblasts
(HFFF2), in order to reproduce cell spreading across the
wound to form a new epithelial layer.
Figure 3 shows representative photomicrographs of
keratinocytes, scratch wounded and exposed to serum-free
medium (0% PL) and 20% PL, at 0, 24 and 72 hours. A
significant effect on scratch closure was observed with all PL
concentrations as compared to 0% PL, starting from 18 hours
(Figure 4). Scratch wounded cells incubated with 10% and 20%
PL for 48 and 72 hours showed a significant higher scratch
closure as compared to 5% PL, comparable to complete
medium (positive control). No significant difference was
observed between 10 and 20% PL treatment at each time-
point.
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Incubation of fibroblasts with different PL concentration
induced a similar migration rate (data not shown).
In vitro angiogenesis assay
The angiogenic capability of human endothelial cells after PL
pre-treatment was evaluated after 8 hours on matrigel (Figure
5). HUVEC preincubation in serum-free medium (0% PL)
significantly decreased angiogenic capability as compared to
the complete medium. Cells pre-incubated with 20% PL
exhibited the highest tubule-forming capability in terms of
morphometric parameters (area %, Figure 5A; number of
branching points, Figure 5B; total tubule length, Figure 5C),
which was comparable to those of cells incubated with
complete medium. A non significant increase in morphometric
parameters was observed with 10% PL, as compared to 0%
PL.
Activation of intracellular pathways and inflammatory
response
10% PL induced ERK1/2 activation in HUVECs starting from
15 min (p<0.05 vs. 0% PL), with a constant value at 30 min
(p<0.05 vs. 0% PL) and a decrease at 60 min (p<0.05 vs. 15
and 30 min); 20% PL effect was comparable (p<0.005 vs. 0%
PL), except at 60 min, when the decrease was much less
Figure 1.  HUVEC viability and proliferation.  HUVEC viability (A) and proliferation (B) were assessed by XTT assay and BrdU
incorporation assay, respectively, following 48 hours of incubation with different PL concentrations (1, 5, 10 and 20%). The
percentage of cell viability and proliferation were calculated versus the complete medium (assumed as 100%). Data are means ±
SD of values obtained from three independent experiments with six replicates each. * p<0.01 vs. serum-free medium, 1 and 5%
PL. .
doi: 10.1371/journal.pone.0084753.g001
Figure 2.  Monocyte chemotaxis assay.  The chemotactic effect of PL on monocytes was assessed following 2 hours of cell
migration towards different PL concentrations (5, 10 and 20%). Positive and negative controls are represented by 10 ng/ml MCP-1
and by serum-free medium, respectively. Data (n=3) are means ± SD of six replicates. * p<0.05 vs. both serum-free medium and
5% PL. .
doi: 10.1371/journal.pone.0084753.g002
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marked (p<0.05 vs. 15 min) (Figure 6A). The effect was
comparable to the positive control at 15 min for both PL
concentrations, while at 30 min ERK1/2 activation was
significantly higher for 20% PL (p<0.001 vs. positive control).
Regarding NFκB, two major phosphorylation sites (Ser 468
and Ser 536) of p65 subunit were evaluated. As a whole, PL
activated NFκB at both phosphorylation sites. At Ser468
(Figure 6B), although the trend was similar for both PL
concentrations, 10% PL significantly induced activation only at
1 and 48 hours (p<0.01 vs. 0% PL ), while 20% PL effect on
activation was significant at every time-point (1 hour: p<0.01;
24 hours: p<0.05; 48 hours: p<0.01 all vs. 0% PL). At 48 hours,
activation was significantly increased compared to the former
time-points for both PL concentrations (p<0.005). At Ser536
Figure 3.  Scratch closure assay.  Representative phase contrast micrographs of 0 and 20% PL-treated keratinocytes at 0, 24 and
72 hours are shown. Scale bar: 200 μm.
doi: 10.1371/journal.pone.0084753.g003
Figure 4.  Scratch closure rate.  Quantification of the effect of PL on scratch closure. A progressive closure was observed with PL
treatment, starting from 18 hours. Scratch wounded cells incubated with 10% and 20% PL for 48 and 72 hours showed a significant
higher scratch closure as compared to 5% PL, comparable to complete medium (positive control). *: p<0.05; **: p<0.005, all vs. 0%
PL. α: p<0.05 vs. 5% PL. Bars represent the means ± SD of values obtained from three independent experiments each one with
three replicates per group of treatment. Closure rates are expressed as percentage of scratch closure after 6, 18, 24, 48 and 72
hours compared to the initial area.
doi: 10.1371/journal.pone.0084753.g004
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(Figure 6C), the effect of the two concentrations was
comparable at 1 and 24 hours (p<0.05 vs. 0% PL), diverging at
48 hours (10% PL: p<0.05; 20% PL: p<0.0001, all vs. 0% PL;
20% PL: p<0.01 vs. 24 hours), with a significant increase in
activation for 20% PL (p<0.05 vs. 10% PL). Activation was also
higher as compared to the complete medium (p<0.05).
Discussion
Wound healing is a complex and dynamic process including
inflammation, proliferation and remodeling, with crucial
signaling pathways. It is generally accepted that growth factors
and cytokines have an essential role as regulators of basic cell
functions [2]. The role of human platelet growth factors in
different stages of the wound healing cascade has been widely
demonstrated. Thus, PDGF delivered in a topical aqueous-
based gel (Regranex, Ethicon, Inc., Irvine, CA) has received
FDA approval for treatment of limb diabetic ulcers [14] and
TGF-β has been tested in several clinical studies [15].
However, the use of single growth factors has shown limited
success and heterogeneous clinical results [2], encouraging
the use of a combination of biological mediators, as
represented by platelet derivatives, for efficient tissue
regeneration.
PL, obtained by freezing/thawing platelets, has been shown
to deliver more growth factors compared with PRP [16].
However, it is essential to standardize platelet derivatives to
evaluate the effectiveness of treatments. The complexity of
establishing parameters is linked to variability and
bioavailability of mediators in platelets and to variability in
product preparation. Recently, the content of 1×109 platelets/ml
has been proposed as a reference realistic parameter [17]. The
allogeneic product that we used for this study matched this
parameter as platelet content was 1.3×109/ml. In view of clinical
setting, it is preferable that PL is manufactured according to the
same strict regulations as practiced in the blood processing
departments of blood banks and the general hospital
environment [18]. PL was obtained from healthy donors,
offering an advantage over patient derivatives. A pool of donors
was used to minimize individual variability. We evaluated the
concentration of growth factors playing a key role in wound
healing because of their effect on different cellular activities
and biological responses [19-21]. PDGF-AB, TGF-β1 and
VEGF amounts resulted in the same order of size of previous
studies on PL [16,22]. Skin wound healing requires recruitment
or activity of different cell types involved in different stages of
this process, such as keratinocytes, endothelial cells,
fibroblasts and inflammatory cells. In the present study, we
Figure 5.  Angiogenesis assay.  The effect on HUVECs of 10% or 20% PL-pre-treatment in serum-free medium for 48 hours,
followed by seeding on Matrigel, is shown. The following morphometric parameters were evaluated after 8 hours of angiogenesis
assay by AngioJ analysis: area % (A), branching points (B), total tubule length (C). Data are expressed as mean±SD of three
independent experiments carried out in duplicate. The 20% PL significantly increased morphometric parameters (p<0.05 vs. 0% PL)
comparably to the complete medium. A non significant increase was observed with 10% PL.
doi: 10.1371/journal.pone.0084753.g005
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evaluated the in vitro effect of different concentrations of PL,
ranging from 1% to 20%, on proliferation and activity of such
cell types. Unlike previous studies that were performed adding
PL to FBS-containing media [12,23], we evaluated PL effects in
absence of serum and growth factors. Cell viability and
proliferation, evaluated by XTT and BrdU assay, and cell
migration induction, determined by monocyte chemotaxis and
scratch wound experiments, revealed that PL at 10% and 20%
promotes cell activity, accelerating in vitro wound healing of
various cell types. The results we obtained on viability and
activities of different human adult cells may support the use of
PL as a substitute for both FBS and growth factors. However,
PL concentration, must be accurately chosen, as its effects are
dose-related.
Platelets play a critical role in regulating angiogenesis in
wound healing. As platelet alpha granules contain several
growth factors and chemokines that positively and negatively
regulate angiogenesis, a spatial-temporal control of the release
of angiogenic regulators to allow for a balance of anti- and pro-
angiogenic factors is required [24].
Although the angiogenic effect of single platelet factors has
been extensively studied, there are few data available on the
angiogenic effect of platelet derivatives as PL. Stabilized
freeze-dried platelets were able to induce tubule formation as
the freeze-drying process preserved growth factors essential
for wound healing, such as PDGF-BB and TGF-β1 in quantities
similar to fresh platelets [25]. The differential release of
angiogenesis stimulators and inhibitors from platelets was also
studied, showing that activation with adenosine diphosphate
stimulated the release of VEGF but not endostatin, promoting
capillary tube formation [26]. A very recent study evaluated
platelet-stimulated angiogenesis focusing mainly on the release
of angiogenesis-regulating factors from their α-granules upon
aggregation [27].
In our study, we treated endothelial cells with the higher PL
concentrations (10% and 20%), demonstrating that PL affects
angiogenesis, as shown by matrigel in vitro assay.
Interestingly, while both 10% and 20% PL significantly
increased cell viability and proliferation, they did not have the
same effect on angiogenesis, as only 20% PL, corresponding
to a physiological platelet concentration, showed a significant
Figure 6.  Activation of intracellular pathways and inflammatory response.  Time-course of ERK1/2 and NFκB phosphorylation
after 10% or 20% PL treatment of HUVECs. Data are expressed as mean±SD of the ratio between the absorbance referred to the
phosphorylated form and to the corresponding total protein. (A) Phosphorylation of ERK1/2. *: p<0.05; **: p<0.005, all vs. 0% PL. #:
p<0.05 vs. both 15 and 30 min. α: p<0.001 vs. complete medium. (B) Phosphorylation of NFκB at Ser 468. *: p<0.05; **: p<0.01, all
vs. 0% PL. #: p<0.005 vs. both 1 and 24 hours. α: p<0.05; αα: p<0.01, all vs. complete medium. (C) Phosphorylation of NFκB at Ser
536. *: p<0.05; **: p<0.0001, all vs. 0%PL. &: p<0.05 vs. 10% PL. #: p<0.05; ##: p<0.005, all vs. 1 hour. °: p<0.01 vs. 24 hours. α:
p<0.05 vs. complete medium.
doi: 10.1371/journal.pone.0084753.g006
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promoting effect. The non-significant effect of 10% PL could be
explained by a lower amount of pro-angiogenic factors and/or
by a different regulation of the pathways involved in the
angiogenesis process.
Another advantage of the use of platelet derivatives has
been proposed recently. Platelet-derived preparations might
accelerate regeneration of difficult-to-heal wounds by triggering
an inflammatory cascade and playing an antimicrobial role
[28,29]. For this reason, we evaluated in endothelial cells the
activation of important inflammatory pathways involved in both
angiogenesis and tissue repair such as ERK1/2 and NFκB,
performing a quantitative and highly sensitive non-radioactive
assay that does not require cell extraction. ERK1/2 signaling
cascade activates many nuclear transcription factors,
mediating response to different growth factors such as VEGF
to coordinate and regulate multiple cell functions, initiating a
complex and integrated network of signaling pathways [30].
ERK1/2 is crucial for cutaneous wound healing [31], as it is
itself activated in response to injury and phosphorylated by
growth factors involved in this process, such the ones
produced by platelets [32]. The transcription factor NFκB, a key
component for the expression of many cellular genes, has
been implicated in the signaling pathways of several growth
factors produced by platelets, controlling cytokine expression
and regulating inflammatory response, with effects on corneal
wound healing and angiogenesis [33]. Gene silencing of NFκB
was shown to impair in vitro wound healing by keratinocytes
[34]; moreover, natural products also used for wound healing,
were able to exert potent antiproliferative and antiangiogenic
activity by blocking the NFκB cascade in different cell types,
including endothelial cells [35]. The interconnection of
inflammation and angiogenesis was also demonstrated for
substances able to reduce NFκB activation by VEGF and to
inhibit the angiogenic cascade both in vitro and in vivo [36].
Our results showed that PL treatment of endothelial cells
was able to stimulate both ERK1/2 and NFκB pathways. While
both PL concentrations induced activation with the same early
kinetics, the effect was different for later time-points, where
only 20% PL induced a sustained activation status. To our
knowledge, this is the first demonstration of NFκB activation in
endothelial cells after PL treatment. However, some previous
studies investigated PL effect on ERK1/2 and NFκB in cells
involved in wound healing. A sustained activation of ERK1/2
had been demonstrated for endothelial cells when 20% PL was
added to FBS-containing medium, showing that the effect of PL
occurs through the stimulation of cell proliferation and
migration, in a process strictly ERK1/2-dependent [23]. PL
activation of ERK1/2 and NFκB pathways had been
demonstrated in two separate studies in keratinocytes. In
particular, the study by El Backly and coworkers [28] showed
that 5% PL, approximately corresponding to a physiologic
platelet concentration in the prelysate platelet suspension,
exerted the highest effect on wound closure, associated with
activation of NFκB. Both sub-physiologic (1%) and higher-than-
physiologic (20%) concentrations resulted in a delaying effect,
pointing to a dose-dependent effect of PL. As the PL used by
these authors is more concentrated than the one we used
(1x1010 vs. 1.3x109 platelets/ml), their results are in accordance
with our experiments. Another study showed only ERK1/2
involvement with no variation of NFκB phosphorylation in
keratinocytes, whereas a slight but significant NFκB
inactivation was observed in fibroblasts [37], a result that adds
to demonstration of ERK1/2 activation in this cell type [12].
PL effect on different cells involved in wound repair supports
this application for this platelet derivative; nevertheless, rapid
leakage and short half-life of growth factors limits PL clinical
application. Moreover, a chronic wound environment can
induce premature growth factor degradation and inactivation
caused by elevated levels of matrix metalloproteinase activity
[38]. As PL efficacy is dependent on its availability to the
injured tissue, a direct delivery at the wound site through
controlled-release systems would enhance PL biological
effects, protecting growth factors from enzymatic degradation
and providing sustained delivery without loss of bioactivity.
Recent studies evaluated this experimental approach. A PL-
impregnated collagen/gelatin scaffold was investigated for
wound repair, assessing PL optimal concentration [39]. PDGF-
BB and TGF-β1 were released from the scaffold in a sustained
manner after collagenase treatment. A 2x concentrated PL
accelerated wound healing and enhanced cell proliferation and
vessel growth, promoting the formation of dermis-like tissue.
Another study concerned the development of sponge-like
dressings, obtained by freeze-drying, based on chitosan
glutamate and sodium hyaluronate for PL delivery to chronic
skin wounds [40]. The effect of dressings loaded with PL on
fibroblast proliferation and PDGF-AB release was compared
with values observed for fresh PL, confirming dressing
capability to maintain unaltered platelet growth factors.
Conclusions
These data bring further scientific support to possible clinical
application of platelet derivatives, suggesting the use of
allogeneic PL for regenerative application. The use of PL for
wound healing is supported by its effect on the activities of
different cell types involved in this process. PL was able to
substitute growth supplements such as FBS and growth
factors, with a dose-related effect, with peculiar characteristics
at the higher PL concentration evaluated. The use of a pool of
healthy donors could minimize individual variability,
representing also an advantage as compared to patients
derivatives, encouraging application of allogeneic products.
The development of controlled-release systems to protect
growth factors and provide sustained delivery would enhance
PL biological effects for clinical application in wound healing.
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